Cormorant Asset Management’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Cormorant Asset Management’s Portfolio ARNA Stock Details ARNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-20,000	Closed	-$1.39M	–	132
2021 Q1	$1.39M	Hold	20,000	–	–	0.03%	112
2020 Q4	$1.54M	Sell	20,000 -10,000	-33%	-$750K	0.04%	97
2020 Q3	$2.24M	Sell	30,000 -45,000	-60%	-$3M	0.09%	86
2020 Q2	$4.72M	Sell	75,000 -25,000	-25%	-$1.38M	0.18%	70
2020 Q1	$4.2M	Sell	100,000 -72,300	-42%	-$3.31M	0.2%	60
2019 Q4	$7.83M	Hold	172,300	–	–	0.31%	53
2019 Q3	$7.89M	Sell	172,300 -27,700	-14%	-$1.56M	0.48%	50
2019 Q2	$11.7M	Sell	200,000 -50,000	-20%	-$2.58M	0.67%	44
2019 Q1	$11.2M	Sell	250,000 -50,000	-17%	-$2.29M	0.76%	41
2018 Q4	$11.7M	Sell	300,000 -110,000	-27%	-$4.32M	0.95%	34
2018 Q3	$18.9M	Sell	410,000 -40,000	-9%	-$1.62M	1.23%	30
2018 Q2	$19.6M	Buy	450,000 +325,000	+260%	+$14M	1.45%	25
2018 Q1	$4.94M	Buy	+125,000	New	+$4.86M	0.37%	41

Other funds holding ARNA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cormorant Asset Management's ARNA Position: Q2 2021 in Review

Cormorant Asset Management sold out of Arena Pharmaceuticals Inc (ARNA) in Q2 2021, closing a stake of 20,000 shares — an estimated $1.39M sold.

Cormorant Asset Management first reported a position in ARNA in Q1 2018 and held it in 13 quarters. The position peaked at $19.6M in Q2 2018. 237 funds tracked by Wall St. Rank hold ARNA as of Q2 2021.

Cormorant Asset Management reported no remaining Arena Pharmaceuticals Inc position as of Q2 2021 after selling out during the quarter.
Cormorant Asset Management sold 20,000 Arena Pharmaceuticals Inc shares in Q2 2021, an estimated $1.39M.
Cormorant Asset Management first reported a position in Arena Pharmaceuticals Inc in Q1 2018 and held it in 13 quarters.
Cormorant Asset Management's Arena Pharmaceuticals Inc position peaked at $19.6M in Q2 2018.
237 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q2 2021.

Based on Cormorant Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.